Sponsor: Alliance Foundation Trials LLC
Sponsor Study ID: UW24152
Study Title: Evaluating the Impact of TrialTalk to Foster Equitable Cancer Care Delivery and Clinical Trial Participation
CTO #: 104244
NCT Number: NCT06985953
Phase: N/A
Protocol Type: Health Services Research
Age Group: Adults
Disease Sites: Anus; Bladder; Bones and Joints; Brain and Nervous System; Breast; Cervix Uteri; Colon; Corpus Uteri; Esophagus; Eye and Orbit; Hodgkin's Lymphoma; Ill-Defined Sites; Kaposi's Sarcoma; Kidney; Larynx; Leukemia, other; Lip, Oral Cavity and Pharynx; Liver; Lung; Lymphoid Leukemia; Melanoma, Skin; Multiple Myeloma; Mycosis Fungoides; Myeloid and Monocytic Leukemia; Non-Hodgkin's Lymphoma; Other Digestive Organ; Other Endocrine System; Other Female Genital; Other Hematopoietic; Other Male Genital; Other Respiratory and Intrathoracic Organs; Other Skin; Other Urinary; Ovary; Pancreas; Prostate; Rectum; Small Intestine; Soft Tissue; Stomach; Thyroid; Unknown Sites
Study Objectives: Examine TrialTalk effectiveness by examining the changes in clinical tiral accrual from baseline by race and ethnicity among enrolled providers and at the institution level up to 12 months post- implementation. Examine the implementation outcomes of TrialTalk such as adoption, penetration, fidelity, feasibility, and acceptability with different stakeholder groups.